CytoDyn (CYDY) Amortization - Deferred Charges (2015)
CytoDyn's (CYDY) quarterly Amortization - Deferred Charges came in at $219000.0 in Q2 2015.
CytoDyn (CYDY) Amortization - Deferred Charges (2015) Analysis & Trends
CytoDyn (CYDY) has 1 years of Amortization - Deferred Charges data on file, last reported at $219000.0 in Q2 2015.
- Quarterly Amortization - Deferred Charges changed N/A year-over-year to $219000.0 in Q2 2015, while the trailing twelve-month figure through May 2015 was $219000.0 (changed N/A YoY) and the FY2015 annual result came in at $219000.0, changed N/A from the prior year.
- Amortization - Deferred Charges held at $219000.0 in Q2 2015.
- In the past five years, Amortization - Deferred Charges ranged from a high of $219000.0 in Q2 2015 to a low of $219000.0 in Q2 2015.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortization - Deferred Charges (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2015 | 219,000.00 |
| May 31, 2015 | 219,000.00 |